Rinetason© 50 mcg nasal spray suspension. Each actuation of the pump delivers a metered dose of 50 micrograms of Mometasone furoate (as Mometasone furoate monohydrate). Contains benzalkonium chloride. Indications. In adults and children 3 years of age and older to treat the symptoms of seasonal allergic or perennial allergic rhinitis. In patients who have a history of moderate to severe symptoms of seasonal allergic rhinitis, prophylactic treatment may be initiated up to four weeks prior to the anticipated start of the pollen season. For the symptomatic treatment of nasal polyps in adults 18 years of age and older. Posology. Seasonal or perennial allergic rhinitis. The usual recommended dose is two actuations in each nostril once daily (total dose 200 micrograms). Once symptoms are controlled, dose reduction to one actuation in each nostril (total dose 100 micrograms) may be effective for maintenance. If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of four actuations in each nostril once daily (total dose 400 micrograms). Children between the ages of 3 and 11 years: The usual recommended dose is one actuation (50 micrograms/actuation) in each nostril once daily (total dose 100 micrograms). Nasal polyposis. The usual recommended starting dose for polyposis is two actuations (50 micrograms/actuation) in each nostril once daily (total daily dose of 200 micrograms). If after 5 to 6 weeks symptoms are inadequately controlled, the dose may be increased to a daily dose of two sprays in each nostril twice daily (total daily dose of 400 micrograms). After effective control of symptoms is maintained, the dose should be lowered to once daily. Should not be used in children below age of 18 years. Contraindications. Hypersensitivity to the active substance or to any of the excipients. Presence of untreated localized infection involving the nasal mucosa. Patients who have experienced recent nasal surgery or trauma until healing has occurred. Precautions for use. Should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract, or in untreated fungal, bacterial, systemic viral infections or ocular herpes simplex. As for other nasal steroids, patients using Mometasone furoate nasal spray over long-term period should be examined periodically for possible changes in the nasal mucosa. Inhalation or oral administration of excessive doses of corticosteroids may result in the suppression of hypothalamic-pituitary-adrenal axis function. The safety and efficacy has not been studied for use in the treatment of unilateral polyps, polyps associated with cystic fibrosis, or polyps that completely obstruct the nasal cavities. Patients receiving corticosteroids who are potentially immunosuppressed should be warned of the risk of exposure to certain infections. Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. Rinetason© 50 mcg nasal spray suspension is not recommended during pregnancy. It is unknown whether mometasone furoate/metabolites are excreted in human milk. Adverse Events. Epistaxis, throat irritation, nasal irritation, nasal burning and nasal ulceration, headache. CDS Jan 2017. Availability of presentations may vary between countries. Rinetason© 50 mcg is available in Jamaica.
This site is intended for residents of Central America & Caribbean.